ADVI Analysis: MedPAC January 2024 Meeting

Pharmaceuticals and Biotech Federal And State Policy

January 22, 2024

MedPAC held a meeting January 11-12, 2024 (link). The following relevant topics were discussed:

  • Assessing payment adequacy and updating payments: Physician and other health professional services
  • Assessing payment adequacy and updating payments: Hospital inpatient and outpatient services
  • Medicare Part D: Status report
  • The Medicare Advantage program: Status report
  • Standardizing benefits in Medicare Advantage plans

ADVI Angle

Key takeaways from the January meeting include:

  • Assessing payment adequacy and updating payments: Physician and other health professional services
    • Commissioners reviewed draft recommendations to increase the physician fee schedule rate by half of the Medicare Economic Index and add add-on payments for low-income beneficiaries. Commissioners unanimously voted in favor of the draft recommendations.
  • Assessing payment adequacy and updating payments: Hospital inpatient and outpatient services
    • Commissioners largely agreed with the draft recommendations to increase fees to hospitals for services. Some Commissioners grappled with grouping hospital inpatient and outpatient services and a number expressed the need for these funds to reach healthcare workers directly.
  • Medicare Part D: Status report
    • MedPAC staff reviewed Part D trends and expected changes.
    • Commissioners discussed and recommended additional Part D topics they believe should be included in the staff’s final Part D status report which will be sent to Congress in March.
  • The Medicare Advantage program: Status report
    • Commissioners reviewed and discussed the latest data on Medicare Advantage, including enrollment, market structure, and payments. Commissioners expressed concerns around the high cost and requested additional information on prior authorizations.
  • Standardizing benefits in Medicare Advantage plans
    • Staff provided multiple frameworks for standardizing benefits in Medicare Advantage plans. All Commissioners agreed that the current state was not consumer-friendly, and many Commissioners agreed with a framework that limited the number of plans per carrier.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.